• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类 Toll 样受体 8 激动剂和拮抗剂之间化学模式的细微差异:新兴化学模式分析。

Subtle differences in chemical pattern between human toll-like receptor 8 agonists and antagonists: Emerging chemical patterns analysis.

机构信息

Key Laboratory of Biorheological Science and Technology (Ministry of Education), Chongqing University, Chongqing, China.

College of Bioengineering, Chongqing University, Chongqing, China.

出版信息

Chem Biol Drug Des. 2019 Oct;94(4):1824-1834. doi: 10.1111/cbdd.13590. Epub 2019 Aug 9.

DOI:10.1111/cbdd.13590
PMID:31293023
Abstract

Due to the potencies in the treatments of cancer, infectious diseases, and autoimmune diseases, the developments of human TLR8 (hTLR8) agonists and antagonists have attracted widespread attentions. The hTLR8 agonists and antagonists have similar structures but with completely opposite biological effects. Up to date, the subtle differences in the structures between the hTLR8 agonists and antagonists are still unknown. In this work, emerging chemical pattern (ECP) was successfully used to extract the key chemical patterns of the hTLR8 agonists and antagonists. By using CAEP classifier, an optimal ECP model with only 3 descriptors was established with the overall prediction accuracy larger than 90%. Further hierarchical cluster analysis and molecular docking showed that the H-bond and hydrophobic properties are the key features distinguishing the hTLR8 agonists from antagonists. Comparing with the antagonists, the agonists show stronger specific H-bond properties, while antagonists have stronger non-specific hydrophobic properties. The significant differences in the structural properties may be closely related to the activation/inhibition mechanism of hTLR8.

摘要

由于在癌症、传染病和自身免疫性疾病治疗方面的潜力,人类 TLR8(hTLR8)激动剂和拮抗剂的开发引起了广泛关注。hTLR8 激动剂和拮抗剂具有相似的结构,但具有完全相反的生物学效应。迄今为止,hTLR8 激动剂和拮抗剂之间结构上的细微差异仍不清楚。在这项工作中,新兴化学模式(ECP)成功地用于提取 hTLR8 激动剂和拮抗剂的关键化学模式。通过使用 CAEP 分类器,建立了一个仅包含 3 个描述符的最佳 ECP 模型,总体预测准确性大于 90%。进一步的层次聚类分析和分子对接表明,氢键和疏水性是区分 hTLR8 激动剂和拮抗剂的关键特征。与拮抗剂相比,激动剂表现出更强的特定氢键性质,而拮抗剂具有更强的非特异性疏水性。结构性质的显著差异可能与 hTLR8 的激活/抑制机制密切相关。

相似文献

1
Subtle differences in chemical pattern between human toll-like receptor 8 agonists and antagonists: Emerging chemical patterns analysis.人类 Toll 样受体 8 激动剂和拮抗剂之间化学模式的细微差异:新兴化学模式分析。
Chem Biol Drug Des. 2019 Oct;94(4):1824-1834. doi: 10.1111/cbdd.13590. Epub 2019 Aug 9.
2
Design of anti-BVDV drug based on common chemical features, their interaction, and scaffolds of TLR8 agonists.基于共同化学特征、相互作用以及 TLR8 激动剂支架设计抗 BVDV 药物。
Int J Biol Macromol. 2016 Nov;92:1095-1112. doi: 10.1016/j.ijbiomac.2016.08.022. Epub 2016 Aug 9.
3
Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.基于结构设计具有增强效力和佐剂活性的人TLR8特异性激动剂。
J Med Chem. 2015 Oct 8;58(19):7833-49. doi: 10.1021/acs.jmedchem.5b01087. Epub 2015 Sep 22.
4
The emerging chemical patterns applied in predicting human toll-like receptor 8 agonists.应用于预测人类Toll样受体8激动剂的新兴化学模式。
Medchemcomm. 2018 Sep 21;9(11):1961-1971. doi: 10.1039/c8md00276b. eCollection 2018 Nov 1.
5
Selecting Therapeutic Antisense Oligonucleotides with Gene Targeting and TLR8 Potentiating Bifunctionality.具有基因靶向和 TLR8 增效双功能的治疗性反义寡核苷酸的选择。
Methods Mol Biol. 2023;2691:225-234. doi: 10.1007/978-1-0716-3331-1_17.
6
Targeting the innate immune receptor TLR8 using small-molecule agents.靶向先天免疫受体 TLR8 的小分子药物。
Acta Crystallogr D Struct Biol. 2020 Jul 1;76(Pt 7):621-629. doi: 10.1107/S2059798320006518. Epub 2020 Jun 17.
7
Identification of imidazoquinoline derivative (IQD) interacting sites of porcine TLR8 and the underlying species specificity.鉴定猪 TLR8 与咪唑并喹啉衍生物 (IQD) 相互作用的结合位点及潜在的种属特异性。
Mol Immunol. 2021 Aug;136:45-54. doi: 10.1016/j.molimm.2021.05.008. Epub 2021 May 31.
8
Small-Molecule TLR8 Antagonists via Structure-Based Rational Design.基于结构的合理设计的小分子 TLR8 拮抗剂。
Cell Chem Biol. 2018 Oct 18;25(10):1286-1291.e3. doi: 10.1016/j.chembiol.2018.07.004. Epub 2018 Aug 9.
9
Enrichment assessment of multiple virtual screening strategies for Toll-like receptor 8 agonists based on a maximal unbiased benchmarking data set.基于最大无偏基准数据集的Toll样受体8激动剂多种虚拟筛选策略的富集评估
Chem Biol Drug Des. 2015 Nov;86(5):1226-41. doi: 10.1111/cbdd.12590. Epub 2015 Jul 14.
10
Study on the agonists for the human Toll-like receptor-8 by molecular modeling.基于分子模拟的人Toll样受体8激动剂研究
Mol Biosyst. 2014 Aug;10(8):2202-14. doi: 10.1039/c4mb00183d.

引用本文的文献

1
Immunotherapeutic Implications of Toll-like Receptors Activation in Tumor Microenvironment.Toll样受体激活在肿瘤微环境中的免疫治疗意义
Pharmaceutics. 2022 Oct 25;14(11):2285. doi: 10.3390/pharmaceutics14112285.